Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on dermatological conditions, with its primary political signal being $5.03M in payments to doctors in 2024 and a single congressional trader executing offsetting trades.
BusinessWhat ARQT does
Arcutis Biotherapeutics develops and commercializes treatments for immune-mediated dermatological diseases. Its revenue is derived from product sales of its approved topical therapies and pipeline development. The company operates in the highly regulated pharmaceutical sector, subject to FDA oversight and drug pricing legislation.
12 months past · 3 months futureARQT activity timeline
Lifetime Government AwardsARQT federal contracts
ARQT doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding ARQT
Politicians Trading ARQTMembers of Congress with recent ARQT positions
Congressional TradesWho in Congress is trading ARQT
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting ARQTLive legislation impacting this stock
Political ProfileWhere ARQT sits in Washington
[object Object]
STRUCTURAL: High regulatory density (95) from pharma sector and 8 identified revenue-impacting bills. No federal contracts, lobbying spend, or political donations. EVIDENTIARY: Significant doctor payments ($5.03M across 47,756 payments in 2024). Single congressional trader (C001123) with offsetting buy/sell transactions. Seven corporate insider buys in the last 180 days, all from non-C-suite personnel, totaling ~$313k. Net: High structural regulatory risk is offset by no direct political engagement and mixed, low-conviction trading signals.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Drug pricing and reimbursement legislationCongress, HHS/CMS"Recent bill_impacts list 8 pharma-sector bills with estimated revenue impacts up to $19.5M."
Regulatory opportunities
-
FDA approval and labeling for pipeline dermatology productsFDA"Sector classification and lack of direct carveouts in `Recent bill_carveouts` suggests standard regulatory pathway is primary interface."
Capitol Hill AlliesChampions & critics
Congressional champions
- Unknown Unknown
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for ARQT — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades ARQT
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord